Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy

Po-Jung Su, Min-Hsien Wu, Hung-Ming Wang, Chia-Lin Lee, Wen-Kuan Huang, Chiao-En Wu, Hsien-Kun Chang, Yin-Kai Chao, Chen-Kan Tseng, Tzu-Keng Chiu, Nina Ming-Jung Lin, Siou-Ru Ye, Jane Ying-Chieh Lee, Chia-Hsun Hsieh, Po-Jung Su, Min-Hsien Wu, Hung-Ming Wang, Chia-Lin Lee, Wen-Kuan Huang, Chiao-En Wu, Hsien-Kun Chang, Yin-Kai Chao, Chen-Kan Tseng, Tzu-Keng Chiu, Nina Ming-Jung Lin, Siou-Ru Ye, Jane Ying-Chieh Lee, Chia-Hsun Hsieh

Abstract

The role of circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent chemoradiotherapy (CCRT) remains uncertain. A negative selection protocol plus flow cytometry was validated to efficiently identify CTCs. The CTC number was calculated and analysed for survival impact. The protocol's efficacy in CTC identification was validated with a recovery rate of 44.6 ± 9.1% and a coefficient of variation of 20.4%. Fifty-seven patients and 20 healthy donors were enrolled. Initial staging, first response to CRT, and surgery after CRT were prognostic for overall survival, with P values of <0.0001, <0.0001, and <0.0001, respectively. The CTC number of EC patients is significantly higher (P = 0.04) than that of healthy donors. Multivariate analysis for disease-specific progression-free survival showed that surgery after response to CCRT, initial stage, and CTC number (≥21.0 cells/mL) played independent prognostic roles. For overall survival, surgery after CCRT, performance status, initial stage, and CTC number were significant independent prognostic factors. In conclusion, a negative selection plus flow cytometry protocol efficiently detected CTCs. The CTC number before CCRT was an independent prognostic factor in patients with unresectable oesophageal squamous cell carcinoma. Further large-scale prospective studies for validation are warranted.

Figures

Figure 1. Illustration of circulating tumour cell…
Figure 1. Illustration of circulating tumour cell (CTC) detection protocol.
Figure 2. The correlations among tumour staging,…
Figure 2. The correlations among tumour staging, response, surgery, unresectable status and survival.
Panel A demonstrates that initial TNM staging correlates with overall survival (OS). Treatment response after concurrent chemoradiotherapy (CCRT) also correlates with OS (Panel B). Residual tumour with or without surgery is also highly prognostic for OS (Panel C); patients with initial T4b and M1 status are excluded (Panel D).
Figure 3. The number of circulating tumour…
Figure 3. The number of circulating tumour cells (CTCs) can differentiate oesophageal cancer patients and its impact on survival.
The method of circulating tumour cell (CTC) detection can differentiate healthy individuals from patients with advanced oesophageal cancer with a P value of 0.04 using the Mann-Whitney U test (Panel A). Panels B and C show that patients with a lower pre-treatment CTC number have longer disease-specific progression-free survival or overall survival. Given the CTC status (score zero for CTC number less than 21.0 cells/mL; 1 for CTC number ≥ 21.0 cells/mL) and response after concurrent chemoradiotherapy (CCRT, score zero for complete remission; 1 for partial response; 2 for stable disease, and 3 for progressive disease), the summation of the CTC score and the score of response to CCRT is defined as the circulating tumour cell plus response (CTCR) score, and this score highly correlates with overall survival with a log rank test P value of

References

    1. Siegel R. L., Miller K. D. & Jemal A. Cancer statistics, 2015. CA Cancer J Clin 65, 5–29 (2015).
    1. Castro C. et al. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980–2011) and predictions to 2015. Ann Oncol 25, 283–290 (2014).
    1. Bosetti C. et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122, 1118–1129 (2008).
    1. World Health Organization Statistical Information System. WHO Mortality Database. Available at (Accessed: 25th November 2015).
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Esophageal cancer, version 3. Available at . (Accessed: 30th December 2015).
    1. Versteijne E. et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus 28, 453–459 (2015).
    1. Ikeda E. et al. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 41, 964–972 (2011).
    1. Akl F. M., Elsayed-Abd-Alkhalek S. & Salah T. Palliative concurrent chemoradiotherapy in locally advanced and metastatic esophageal cancer patients with dysphagia. Ann Palliat Med 2, 118–123 (2013).
    1. Aiko S. et al. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Dis Esophagus 20, 94–101 (2007).
    1. Park J. W. et al. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 81, 691–697 (2011).
    1. Shitara K. et al. Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci 101, 1001–1006 (2010).
    1. Jiang Z. et al. Serum microRNA-218 is a potential biomarker for esophageal cancer. Cancer Biomark 15, 381–389 (2015).
    1. Wang C. et al. Clinical potential of miR-3651 as a novel prognostic biomarker for esophageal squamous cell cancer. Biochem Biophys Res Commun 465, 30–34 (2015).
    1. Oshima Y. et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51, 30–34 (2016).
    1. Jin Y. et al. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asia Pac J Clin Oncol 11, e37–e41 (2015).
    1. Ashworthm T. R. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Australian Med J. 14, 146 (1869).
    1. Yu M. et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216–220 (2014).
    1. Sheng W. et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab on a chip 14, 89–98 (2014).
    1. Cheng M., Liu L., Yang H. S. & Liu G. F. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev 15, 6369–6374 (2014).
    1. Nadal R. et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133, 2398–2407 (2013).
    1. Yu K. H. et al. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res 20, 5281–5289 (2014).
    1. Abdallah E. A. et al. Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer 137, 1397–1405 (2015).
    1. Gradilone A. et al. How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment. Am J Clin Oncol 34, 625–627 (2011).
    1. Lu C. Y. et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer 108, 791–797 (2013).
    1. Krebs M. G. et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29, 1556–1563 (2011).
    1. Matsushita D. et al. Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 22, 3674–3680 (2015).
    1. Ma X. et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol 35, 5551–5560 (2014).
    1. Hsieh J. C. et al. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head & neck 37, 1448–1455 (2015).
    1. Friedlander T. W. et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 134, 2284–2293 (2014).
    1. Musella V. et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer 137, 1467–1474 (2015).
    1. Stec M. et al. Isolation and characterization of circulating micro(nano)vesicles in the plasma of colorectal cancer patients and their interactions with tumor cells. Oncol Rep 34, 2768–2775 (2015).
    1. Alix-Panabieres C. & Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab on a chip 14, 57–62 (2014).
    1. Huang S. B. et al. High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab on a chip 13, 1371–1383 (2013).
    1. Chiu T. K. et al. Development of a microfluidic-based optical sensing device for label-free detection of circulating tumor cells (CTCs) through their lactic acid metabolism. Sensors (Basel) 15, 6789–6806 (2015).
    1. Barbazan J. et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 135, 2633–2643 (2014).
    1. Zhang Y. et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer 136, 1228–1233 (2015).
    1. Andreopoulou E. et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 130, 1590–1597 (2012).
    1. McShane L. M. et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93, 387–391 (2005).
    1. Koike M. et al. Molecular detection of circulating esophageal squamous cell cancer cells in the peripheral blood. Clin Cancer Res 8, 2879–2882 (2002).
    1. Nakashima S. et al. Clinical significance of circulating tumor cells in blood by molecular detection and tumor markers in esophageal cancer. Surgery 133, 162–169 (2003).
    1. Ito H. et al. Detection and quantification of circulating tumor cells in patients with esophageal cancer by real-time polymerase chain reaction. J Exp Clin Cancer Res 23, 455–464 (2004).
    1. Liu Z., Jiang M., Zhao J. & Ju H. Circulating tumor cells in perioperative esophageal cancer patients: quantitative assay system and potential clinical utility. Clin Cancer Res 13, 2992–2997 (2007).
    1. Bobek V. et al. Cultivation of circulating tumor cells in esophageal cancer. Folia Histochem Cytobiol 52, 171–177 (2014).
    1. Reeh M. et al. Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer. Ann Surg 261, 1124–1130 (2015).
    1. Tanaka M. et al. Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. Esophagus 12, 352–359 (2015).
    1. Bureau of Health Promotion, Department of Health, the Executive Yuan, Taiwan. Cancer Registry Annual Report in 2012, Taiwan. Available at: . (Accessed: February 2015).
    1. Lee C. H. et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer 113, 475–482 (2005).
    1. Mostert B. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 133, 130–141 (2013).
    1. Kanwar N. et al. Identification of genomic signatures in circulating tumor cells from breast cancer. Int J Cancer 137, 332–344 (2015).
    1. Allard W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10, 6897–6904 (2004).
    1. Hong B. & Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 3, 377–394 (2013).
    1. Kraan J. et al. External quality assurance of circulating tumor cell enumeration using the CellSearch system: a feasibility study. Cytometry B Clin Cytom 80, 112–118 (2011).
    1. Riethdorf S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13, 920–928 (2007).

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다